Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF 10A | NM | Basal B | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 11056.158 | 0.0039 | -0.7360 | 2.7355 | |
| MCF 10F | NM | - | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12254.165 | 0.9924 | 0.9910 | 1.6980 | |
| MCF 10F | NM | - | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12254.165 | 0.9612 | 0.9540 | 1.6980 | |
| MCF 10F | NM | - | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12254.165 | 1.0302 | 1.0353 | 1.6980 | |
| MCF 10F | NM | - | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12254.165 | 0.8823 | 0.8579 | 1.6980 | |
| MCF 10F | NM | - | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12254.165 | 0.4650 | 0.2740 | 1.6980 | |
| MCF 10F | NM | - | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12254.165 | 0.4248 | 0.2079 | 1.6980 | |
| MCF 10F | NM | - | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12254.165 | 0.3555 | 0.0877 | 1.6980 | |
| MCF 10F | NM | - | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12254.165 | 0.0496 | -0.6589 | 1.6980 | |
| MCF 10F | NM | - | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12254.165 | 0.0058 | -0.9038 | 1.6980 | |
| MCF12A | NM | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12365.165 | 1.0054 | 1.0057 | 1.9114 | |
| MCF12A | NM | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12365.165 | 0.9795 | 0.9784 | 1.9114 | |
| MCF12A | NM | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12365.165 | 0.9581 | 0.9557 | 1.9114 | |
| MCF12A | NM | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12365.165 | 0.8905 | 0.8823 | 1.9114 | |
| MCF12A | NM | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12365.165 | 0.4725 | 0.3511 | 1.9114 | |
| MCF12A | NM | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12365.165 | 0.3384 | 0.1345 | 1.9114 | |
| MCF12A | NM | Basal B | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12365.165 | 0.2907 | 0.0480 | 1.9114 | |
| MCF12A | NM | Basal B | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12365.165 | 0.0450 | -0.6051 | 1.9114 | |
| MCF12A | NM | Basal B | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12365.165 | 0.0091 | -0.8289 | 1.9114 | |
| MDA-MB-134-VI | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12206.158 | 0.9164 | 0.8529 | 1.1431 | |
| MDA-MB-134-VI | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12206.158 | 0.9593 | 0.9286 | 1.1431 | |
| MDA-MB-134-VI | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12206.158 | 0.9513 | 0.9146 | 1.1431 | |
| MDA-MB-134-VI | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12206.158 | 0.9467 | 0.9065 | 1.1431 | |
| MDA-MB-134-VI | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12206.158 | 0.9460 | 0.9051 | 1.1431 | |
| MDA-MB-134-VI | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12206.158 | 0.9659 | 0.9401 | 1.1431 |